Risk Factors and elsewhere in this Form 10-K. All statements, other than statements of historical facts, included herein that address activities, events or developments that the Company expects or anticipates will or may occur in the future, are forward-looking statements, including statements regarding:  Advantages of the human tissues the Company distributes;  Plans, costs and expected timeline regarding regulatory approval for PerClot, and the distribution of PerClot in certain markets after the requisite regulatory approvals are obtained;  Benefits of TMR treatment and the Phoenix System;  Estimates regarding the addressable market opportunity for TMR;  Plans and expected timeline regarding regulatory approval for the Phoenix System;  Anticipated timing of the PEARL 8.0 launch;  Plans regarding acquisition and investment opportunities of complementary product lines and companies;  Plans regarding the licensing of the Companys technology to third parties for non-competing uses;  Potential benefits of the Companys surgical adhesives and sealants;  Plans regarding regulatory approval in certain markets for BioFoam, including the expected timeline and source of funding for related studies, and the subsequent distribution of BioFoam in those markets;  The estimated European and worldwide market for BioFoam;  Commercialization plans for ProPatch;  Expected benefits of the Companys marketing, educational and technical support efforts;  Plans and expected timeline regarding regulatory approval for CryoValve SGPV and CryoValve SGAV, and the benefits of related studies;  Expected use of the Companys additional laboratory space;  The Companys intentions with respect to lawsuits and the expected timeline, costs and impact of current litigation;  Expectations regarding the stock repurchase plan, including market conditions and other factors affecting the plan, and the Companys ability to fund repurchases from working capital and cash flow;  The Companys expectations regarding the recoverability of deferred tax assets;  The Companys estimates of unreported loss liabilities, including the assumptions used to establish those estimates and its belief that those assumptions provide a reasonable basis for the estimates;  The Companys estimates of fair value of acquired assets, and its belief that the estimates are reasonable;  The Companys belief that decreases in shipments of cardiac valves due to increasing pressure from lower cost competitive products will be largely offset by increases in revenues due to its expanded sales staff;  The Companys anticipated significant decrease in total hemostat sales in 2012;  The potential impact of stock repurchases or additional sales of common stock on the Companys stock price;  The expectation that the Company will continue to renew certain acquired contracts and procurement agreements for the foreseeable future;  Estimates and assumptions related to unreported loss liability;  Beliefs regarding the realizability of the Companys deferred tax assets; 37  Expectations regarding the impact of new accounting pronouncements;  Expectations regarding the recognition of stock compensation expense;  Plans and expectations regarding research and development of new technologies and products;  Expected benefits of acquisitions;  Anticipated future demand for our tissues and products;  Beliefs regarding domestic and international BioGlue sales and the factors affecting such sales;  The impact of expenses associated with lawsuits and business development opportunities;  The Companys beliefs regarding the seasonal nature of the demand for some of its products and services;  The adequacy of the Companys financial resources;  The Companys belief that it will have sufficient cash to meet its operational liquidity needs for at least the next twelve months;  The Companys expectations regarding the source of any future payments related to any unreported tissue processing or product liability claims;  Anticipated impact of changes in interest rates and foreign currency exchange rates;  Issues that may impact the Companys future financial performance and cash flows; and  Other statements regarding future plans and strategies, anticipated events, or trends. These statements are based on certain assumptions and analyses made by the Company in light of its experience and its perception of historical trends, current conditions, and expected future developments as well as other factors it believes are appropriate in the circumstances. However, whether actual results and developments will conform with the Companys expectations and predictions is subject to a number of risks and uncertainties which could cause actual results to differ materially from the Companys expectations, including, without limitation, in addition to those specified in the text surrounding such statements, the risk factors discussed in Item 1A of this Form 10-K and other factors, many of which are beyond the control of CryoLife. Consequently, all of the forward-looking statements made in this Form 10-K are qualified by these cautionary statements, and there can be no assurance that the actual results or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequences to or effects on the Company or its business or operations. The Company assumes no obligation to update publicly any such forward-looking statements, whether as a result of new information, future events, or otherwise. 38 Item 1B. Unresolved Staff Comments. The Company has no unresolved written comments received from the staff of the Securities and Exchange Commission regarding its periodic or current reports under the Securities Exchange Act of 1934 not less than 180 days before December 31, 2011 (the end of the fiscal year to which this Form 10-K relates). 